ArticleNature cancer2022
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Open access · hybridAbstract read
In one paragraph
Article in Nature cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 61 citations in OpenAlex.
- Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy.Molecular oncology · 2026Article
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- UniversalEPI: robust prediction of cell type-specific and differential chromatin interactions from DNA sequence and chromatin accessibility.Nucleic acids research · 2026Article
- Differential microRNA expression profiles and predicted miRNA-mRNA regulatory networks in human macrophage-like cells infected with Leishmania infantum.Scientific reports · 2026Article
- Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer.The Journal of clinical investigation · 2026Article
- Targeting the tripartite axis of immune-metabolic-spatial crosstalk to overcome therapy resistance in breast cancer.Frontiers in immunology · 2026Review
- Wnt3a-expressing cancer stem cells impair CD8Oncoimmunology · 2025Article
- Extracellular Vesicle-Based mRNA Therapeutics and Vaccines.Exploration (Beijing, China) · 2025Review
- The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy.Journal of experimental & clinical cancer research : CR · 2025Review
- TIM3Cancer cell · 2025Article
- Cancer stem cells: Bridging microenvironmental interactions and clinical therapy.Clinical and translational medicine · 2025Review
- CXCR4Nature communications · 2025Article
- Targeted nanoparticle delivery system for tumor-associated macrophage reprogramming to enhance TNBC therapy.Cell biology and toxicology · 2025Article
- Cancer stem cells and niches: challenges in immunotherapy resistance.Molecular cancer · 2025Review
- Unveiling the impact of interferon genes on the immune microenvironment of triple-negative breast cancer: identification of therapeutic targets.Frontiers in bioinformatics · 2025Article
- Applications of mRNA Delivery in Cancer Immunotherapy.International journal of nanomedicine · 2025Review
- Identification of the LCOR-PLCL1 pathway that restrains lipid accumulation and tumor progression in clear cell renal cell carcinoma.International journal of biological sciences · 2025Article
- mRNA compartmentalization via multimodule DNA nanostructure assembly augments the immunogenicity and efficacy of cancer mRNA vaccine.Science advances · 2024Article
- Ubiquitin-specific peptidase 22 controls integrin-dependent cancer cell stemness and metastasis.iScience · 2024Article
- CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation-Mediated c-Myc Deubiquitylation to Facilitate Mutant TP53 Transcription.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 13 institutions in 3 countries.
Iván Pérez-NúñezCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Catalina RozalénCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
José Ángel PalomequeCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Irene SangradorCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Mariona DalmauCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Laura ComermaPathology Department, Hospital del Mar, Barcelona, Spain.
Anna Hernández-PratCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
David CasadevallCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Silvia MenendezCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Daniel Dan LiuDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.ORCID http://orcid.org/0000-0003-0100-5973
Minhong ShenDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Jordi BerenguerCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Irene Rius RuizPreclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6097-7572
Raul PeñaCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
José Carlos MontañésResearch Program on Biomedical Informatics, Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Spain.
M Mar AlbàResearch Program on Biomedical Informatics, Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Spain.
Sarah BonninCentre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
Julia PonomarenkoCentre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
Roger R GomisInstitució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6473-2858
Juan Miguel CejalvoCentro de Investigación Biomédica en Red de Oncología, Madrid, Spain.
Sonia ServitjaCentro de Investigación Biomédica en Red de Oncología, Madrid, Spain.
Diego M MarzeseFundació Institut d'Investigació Sanitària Illes Balears, Mallorca, Spain.
Lluis MoreySylvester Comprehensive Cancer Center, Miami, FL, USA.ORCID http://orcid.org/0000-0001-9851-4066
Leonie VoorwerkDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Joaquín ArribasCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0002-0504-0664
Begoña BermejoCentro de Investigación Biomédica en Red de Oncología, Madrid, Spain.
Marleen KokDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-9043-9815
Lajos PusztaiBreast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-9632-6686
Yibin KangDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.ORCID http://orcid.org/0000-0002-1626-6730
Joan AlbanellCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain. jalbanell@hospitaldelmar.cat.ORCID http://orcid.org/0000-0003-1239-4580
Toni Celià-TerrassaCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain. acelia@imim.es.ORCID http://orcid.org/0000-0002-0615-8744
Hospital Del Mar · ESInstitució Catalana de Recerca i Estudis Avançats · ESUniversitat Pompeu Fabra · ESHospital Clínico Universitario de Valencia · ESPrinceton University · USThe Netherlands Cancer Institute · NLCalifornia Institute for Regenerative Medicine · USCentre for Genomic Regulation · ESCentro de Investigación Biomédica en Red · ESHealth Research Institute of the Balearic Islands · ESUniversity of Miami · USVall d'Hebron Institut de Recerca · ESYale Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ligand-dependent corepressor (LCOR) mediates normal and malignant breast stem cell differentiation. Cancer stem cells (CSCs) generate phenotypic heterogeneity and drive therapy resistance, yet their role in immunotherapy is poorly understood. Here we show that immune-checkpoint blockade (ICB) therapy selects for LCOR
Indexed as
Triple Negative Breast NeoplasmsCutaneous Malignant MelanomaHumansImmune Checkpoint InhibitorsImmunotherapyInterferonsMelanomaRepressor ProteinsSkin NeoplasmsImmune Checkpoint InhibitorsInterferonsLCOR protein, humanRepressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.